Cogstate Ltd (AU:CGS)
ASX:CGS
CGS Stock Chart & Stats
AU$2.53
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.53
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$1.21 - AU$2.97
Previous CloseN/A
Volume30.50K
Average Volume (3M)355.93K
Market Cap
AU$410.38M
Enterprise ValueAU$279.04M
Total Cash (Recent Filing)AU$34.07M
Total Debt (Recent Filing)AU$716.74K
Price to Earnings (P/E)20.9
Beta-0.16
Next Earnings
Aug 26, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield0.88%
Share Statistics
EPS (TTM)0.04
Shares Outstanding170,989,670
10 Day Avg. Volume327,690
30 Day Avg. Volume355,934
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)6.26
Price to Sales (P/S)5.90
P/FCF Ratio35.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.18Price Target Upside25.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)AU$59.80M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & CashMinimal leverage and sizable cash provide durable financial optionality. With debt-to-equity at 0.01, equity financing of assets ~74% and $34.1m cash on hand, Cogstate can fund delivery capacity, invest in product development, and withstand trial timing volatility without needing near-term external financing.
High Margins And EfficiencySustained gross and net margins plus strong ROE reflect structural cost efficiency in a software-enabled clinical services model. High margins allow reinvestment in tech/AI and absorb delivery cost increases while preserving long-term profitability as contract mix normalizes.
Scalable Channel Partnerships & DiversificationA partner-driven go-to-market reduces direct sales expense and scales market reach. With channel partners generating the majority of opportunities and growing traction in mood/sleep/psychiatry, Cogstate can diversify revenue across indications and accelerate contract flow without proportionate fixed-cost increases.
Bears Say
Sharp Reported Revenue DeclineA 34% revenue drop signals structural sensitivity to trial timing and contract recognition. Even with improving backlog, such volatility undermines predictable top-line growth, complicates capacity planning and can delay margin recovery if contract conversion timing remains uneven across reporting periods.
Free Cash Flow ContractionA halving of free cash flow reduces internal funding for R&D, delivery scaling and strategic M&A. Even with positive operating cash conversion relative to net income, materially weaker FCF constrains flexibility to accelerate product development or absorb prolonged revenue recognition lags without altering capital return or investment plans.
Concentration & Timing Risk In Core IndicationDependence on episodic large Alzheimer’s trials creates structural revenue cyclicality. When major presymptomatic programs pause or conclude, contract cadence and license fee timing shift materially, forcing the company to rely on diversification and channel growth to stabilize revenues over the medium term.
Cogstate Ltd News
CGS FAQ
What was Cogstate Ltd’s price range in the past 12 months?
Cogstate Ltd lowest share price was AU$1.21 and its highest was AU$2.97 in the past 12 months.
What is Cogstate Ltd’s market cap?
Cogstate Ltd’s market cap is AU$410.38M.
When is Cogstate Ltd’s upcoming earnings report date?
Cogstate Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 138 days.
How were Cogstate Ltd’s earnings last quarter?
Cogstate Ltd released its earnings results on Feb 18, 2026. The company reported AU$0.037 earnings per share for the quarter, beating the consensus estimate of AU$0.03 by AU$0.007.
Is Cogstate Ltd overvalued?
According to Wall Street analysts Cogstate Ltd’s price is currently Undervalued.
Does Cogstate Ltd pay dividends?
Cogstate Ltd pays a Notavailable dividend of AU$0.02 which represents an annual dividend yield of 0.88%. See more information on Cogstate Ltd dividends here
What is Cogstate Ltd’s EPS estimate?
Cogstate Ltd’s EPS estimate is 0.05.
How many shares outstanding does Cogstate Ltd have?
Cogstate Ltd has 170,989,670 shares outstanding.
What happened to Cogstate Ltd’s price movement after its last earnings report?
Cogstate Ltd reported an EPS of AU$0.037 in its last earnings report, beating expectations of AU$0.03. Following the earnings report the stock price went up 8.716%.
Which hedge fund is a major shareholder of Cogstate Ltd?
Currently, no hedge funds are holding shares in AU:CGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogstate Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.18 (25.49% Upside)
AU$3.18 (25.49% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
140.24%
12-Months-Change
Fundamentals
Return on Equity
29.05%
Trailing 12-Months
Asset Growth
12.30%
Trailing 12-Months
Company Description
Cogstate Ltd
Cogstate Ltd (CGS) is a global neuroscience technology company focused on the development and commercialization of cognitive assessment tools and solutions. Operating primarily within the healthcare and pharmaceutical sectors, Cogstate specializes in providing cognitive testing services that are used in clinical trials and clinical practice to measure cognitive function in various populations, including patients with neurological disorders and those undergoing drug trials. The company's core products include digital cognitive assessments that facilitate the evaluation of cognitive performance and the monitoring of cognitive health over time.
CGS Company Deck
CGS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and forward visibility: record new trial starts, a 105% jump in sales contracts, solid YoY revenue/backlog growth, expanding channel partnerships, and a healthy cash balance. Short‑term margin pressure and a $0.5M doubtful debt provision were acknowledged, largely driven by deliberate investments in delivery capacity, timing of contract recognition and one‑off adjustments. Management expects margins to recover in H2 as contracted revenue converts and maintains a clear strategy of diversification and technology investment to sustain medium‑term growth.View all AU:CGS earnings summariesCGS Stock 12 Month Forecast
Average Price Target
AU$3.18
▲(25.49% Upside)
Technical Analysis
Tali Digital
―
Opyl Ltd.
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
PainChek Ltd
―
Options Prices
Currently, No data available
---